Fat Injections

Published on 22/05/2015 by admin

Filed under Plastic Reconstructive Surgery

Last modified 22/05/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 2 (1 votes)

This article have been viewed 2886 times

CHAPTER 26 Fat Injections

Kotaro Yoshimura, Yuko Asano

Key Points

1. Moderate augmentation (100–200 ml) of the breast is successfully achieved by autologous lipoinjection without major complications if appropriately performed in selected patients.
2. Breasts augmented with fat injection are soft and show natural texture and appearance, and patients are free from daily stress and future concerns derived from foreign materials (such as complications and potential implant replacement or removal).
3. Surviving fat volume varies substantially among patients, and multiple factors are likely to affect the clinical results; patient factors include skin redundancy of the breast, quality (such as viability and progenitor richness) of fat grafts, and infiltration techniques are key determinants to clinical results of lipoinjection.
4. Aspirated fat tissue should be appropriately harvested and stored, and quickly processed and infiltrated with proper devices to avoid degradation of the graft tissues and to place aliquots of fat grafts as diffusely as possible.
5. Relative deficiency of adipose progenitor cells in aspirated fat tissue may lead to long-term atrophy of the grafts, and supplementation of vascular stromal fraction containing adipose progenitor cells may boost the efficacy and safety of lipoinjection to the breasts.

Introduction

Autologous fat transplantation is one of the promising cosmetic treatments for facial rejuvenation and soft-tissue augmentation due to the lack of an incisional scar and complications associated with foreign materials. However, certain problems remain, such as unpredictability and a low rate of graft survival due to partial necrosis. It has also been used in breast augmentation by a limited number of plastic surgeons,1 although the use of autologous fat for breast augmentation has been controversial due to the lack of consensus on whether it is safe and appropriate because of microcalcifications that may cause confusion in the evaluation of mammograms.

Implantation of prostheses has been a gold standard for breast augmentation, but complications with artificial materials such as capsular contracture remain to be resolved. The presence of the implant and capsules induced by implants could also affect breast tissue visualization in the mammogram.2 Furthermore, there is potential for rupture when pressure is exerted on the implant during mammography, and for this reason, hospitals in Japan reject women with breast implants to undergo mammography as a part of the annual social health examinations. Recently, autologous fat injection has been re-evaluated as a potential alternative to artificial implants for breast augmentation.1,3 This re-evaluation may reflect recent advances in autologous fat transfer and the radiological detection of breast cancer.

In this chapter, potentials of fat injection for breast augmentation or reconstruction are discussed as well as our novel approach of autologous fat grafting called cell-assisted lipotransfer (CAL);3,4 this is the concurrent transplantation of aspirated fat tissue and adipose progenitor cells.

Patient Selection

There are several patient factors that may affect the clinical result of conventional lipoinjection or CAL: skin redundancy of the breasts, age, body mass index (BMI), individual quality or character of the fat tissue, adhesive scars, breast implant and its capsule, systemic disease such as autoimmune disease, oral corticosteroids, etc.3,5 Good candidates are those who have sufficient fat at donor sites and redundant breast skin with healthy vascularity and without any scars.

Lipoinjection can be performed in any patient from their teens to 70s, but patients with low body mass index (BMI < 17) or athletes with little body fat are not good candidates due to the difficulty in harvesting a large volume of fat tissue. Patients who want a large-volume (250–400 ml) augmentation are not good candidates because augmentation volume achieved by a single session of lipoinjection is limited (100–200 ml).

Some patients are concerned about complications derived from foreign bodies and about possible surgical removal or replacement of implants in the future. Others do not want their history of breast surgery to come out. These patients want to avoid breast implants and do not want a great deal of breast augmentation; they are good candidates for this procedure.

Indications

Operative indications are described below according to three kinds of graft tissue preparations or operative purposes.

Graft tissue preparations

As for lipoinjection, we use conventional lipoinjection (micro-fat grafting) and a new technique; grafting of progenitor-enriched adipose tissue. We call the latter CAL; the concept and details of CAL are described later. There are two types of CAL: mini-CAL and full-CAL; only the fluid portion of liposuction aspirates are used for harvesting adipose progenitor cells in mini-CAL, while another similar volume of liposuction aspirates to graft tissues are used for the cell isolation in full-CAL (Fig. 26.1). Thus, full-CAL requires twice the volume of adipose tissue as the conventional lipoinjection or mini-CAL; approximately 700–800 ml of lipoaspirate are needed for conventional lipoinjection or mini-CAL for both breasts, while 1200–1500 ml lipoaspirate are required for the full-CAL procedure.

image

Fig. 26.1 Scheme of conventional lipoinjection and cell-assisted lipotransfer (CAL).

The adipose portion (yellow) of liposuction aspirates is centrifuged and used as injection material in conventional lipoinjection. In mini-CAL, the fluid portion (pink) of the liposuction aspirate is used for the isolation of the stromal vascular fraction (SVF) containing adipose progenitor cells. In full-CAL, another volume of liposuction aspirate is additionally harvested for SVF isolation. Freshly isolated SVF are used for supplementation of adipose progenitor cells to grafting tissues. (For the supplementation of SVF, see also Figure 26.5.)

If BMI is less than 18 or body weight is less than 45 kg, conventional lipoinjection or mini-CAL is recommended. On the other hand, for patients with BMI > 25, full-CAL is easily performed without concerns for the donor site.

Operative purposes

Breast augmentation

Lipoinjection can be performed without combining any other procedures. We, however, also propose a secondary lipoinjection after 1 year implantation of breast prostheses if patients are very thin, have flat breasts and tight breast skin, because only a small volume lipoinjection can be performed in those cases due to high internal pressure and skin tension after injection.

Breast implant replacement

Lipoinjection can be performed at the same time as implant removal. The implants have to be removed through a periareolar incision, though they can be removed through an axillary incision if lipoinjection is performed separately from implant removal.

Breast reconstruction

Lipoinjection can be performed in any cases, but detailed assessment of tissue and skin conditions of the breasts is necessary before application. In most reconstruction cases with skin shortage, lipoinjection after tissue expansion is recommended; lipoinjection can be performed immediately after removal of the tissue expander. For patients who have sufficiently redundant skin and do not have severe scar tissue or adhesion of the skin to the underlying fascia or any other deep tissues, lipoinjection alone may work successfully. Lipoinjection can also be applied to patients with irradiated skin, though the injection volume is usually limited. Several sessions of lipoinjection can be performed to irradiated breasts with each interval being more than 12 months. Lipoinjection after tissue expansion is also applied to these irradiated patients, but expander implantation under the pectoralis major muscle and a careful expansion are recommended.

Inborn deformity

Simple hypoplastic breasts can be successfully treated with lipoinjection in most cases, but tubular deformity is hard to improve by lipoinjection alone. Funnel chest deformity can be corrected with lipoinjection, though the filling volume by a single surgery is limited and repetitive treatments are usually recommended.

Injection of progenitor-enriched fat tissue: principles and therapeutic concepts of CAL

Cell components of adipose tissue

Adipose tissue consists predominantly of adipocytes, adipose stromal cells (ASC), vascular endothelial cells, pericytes, fibroblasts and extracellular matrix.6 Adipocytes constitute more than 90% of tissue volume, but they are much larger in size than the other cells and the number of adipocytes is estimated to be less than 50%7 (Fig. 26.2). ASC are considered to be adipose tissue-specific progenitor cells (adipogenic and angiogenic progenitors), some of which have been shown to differentiate into multiple lineages and are now called adipose-derived stem cells.8 ASC contribute to adipose tissue turnover (adipose tissue is thought to turn over every 2–10 years9,10) and provide cells for the next generation. ASC are currently being used in various clinical trials, including treatments for rectovaginal fistula (autologous cultured ASC)11 and graft-versus-host disease (non-autologous ASC).12 If ASC are harvested from a large volume (e.g., 500 ml) of liposuction aspirates, ASC can be used clinically without cell expansion because a sufficient number of cells can be obtained. The use of minimally manipulated fresh cells may lead to higher safety and efficacy in actual treatments.

image

Fig. 26.2 Scheme of adipose tissue components.

Adipocytes constitute more than 90% of tissue volume, but only less than 50% of cells in number. Adipose-derived stromal/stem cells (ASC), endothelial cells, fibroblasts, and other cells constitute the rest of cell components. The extracellular matrix (ECM) of the adipose tissue contains collagen, laminin, fibrinogen, etc.

Aspirated fat tissue versus intact fat tissue

We can use aspirated fat tissue as lipoinjection material but not excised fat tissue. Aspirated fat is fragile parts of the adipose tissue taken with negative pressure. Our research revealed that aspirated fat tissue contains only half the number of ASC compared to intact fat tissue4 (Fig. 26.3). The two main reasons for this relative deficiency of ASC contained in aspirated fat tissue are: (1) a major portion of ASC are located around large vessels (within the tunica adventitia) and left in the donor tissue, and (2) some ASC are released into the fluid portion of liposuction aspirates.6 Our histological study indicated that ASC are located not only between adipocytes but also around vessels. Large-sized vessels are located in the fibrous part of the tissue, which contains intact fat tissue but not aspirated fat tissue. Thus, aspirated fat tissue is regarded as relatively progenitor-poor fat tissue compared to intact fat tissue.4

image

Fig. 26.3 Comparison of human intact fat tissue and aspirated fat tissue obtained from a single site of a single patient.

Schematic views (top), electron microscopic and whole mount staining images (middle), and isolated progenitor cells (bottom). The basic structure of adipose tissue was preserved in the aspirated fat, while vascular vessels, especially those of large size, were significantly less detected in aspirated fat compared to the excised fat. It is well known that the honeycomb structures of vascular and neural perforator networks are left intact in aspirated sites after liposuction operation. ASC yield from aspirated fat tissue was significantly less (56 ± 12%) than that from excised fat tissue.

Stromal vascular fraction

Through collagenase digestion a heterogeneous cell mixture, which contains cell types other than adipocytes, can be extracted from adipose tissue as a cell pellet. This cell fraction is called the stromal vascular fraction (SVF) (Fig. 26.4), because they are basically stromal cells and contain vascular endothelial and mural cells. In the clinical setting SVF contains a substantial amount of blood-derived cells, such as leukocytes and erythrocytes, as well as adipose-derived cells such as ASC and vascular endothelial cells.6 Our study revealed that nucleate cells contained in the SVF are composed of 37% leukocytes, 35% ASC, 15% endothelial cells and other cells, though the percentage of blood-derived cells strongly depends on individual hemorrhage volume.7

Buy Membership for Plastic Reconstructive Surgery Category to continue reading. Learn more here

Related posts:

Oncologic Considerations for Breast Reconstruction Superomedial Pedicle Breast Reduction Using a Vertical Pattern Inferior-central Flap Mastopexy with Pectoralis Strip TRAM Flap Variations in Breast Reconstruction Mastopexy after Implant Removal Superomedial Pedicle Extension Mastopexy